Natural Product (NP) Details

General Information of the NP (ID: NP3410)
Name
Progesterone
Synonyms
progesterone; 57-83-0; Pregn-4-ene-3,20-dione; Agolutin; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Corpus luteum hormone; Syngesterone; Utrogestan; Luteol; Glanducorpin; Pregnenedione; Progesterol; Syngestrets; Corlutin; Cyclogest; Gesterol; Gestone; Gestormone; Progestin; Progestone; Progestron; Prometrium; Hormoflaveine; Methylpregnone; Progestasert; Progesteronum; Progestronol; Corlutina; Corluvite; Corporin; Flavolutan; Fologenon; Gynlutin; Gynolutone; Hormoluton; Lingusorbs; Lucorteum; Luteodyn; Luteogan; Luteopur; Luteosan; Luteostab; Luteovis; Lutociclina; Lutocyclin; Lutocylin; Lutoform; Lutromone; Membrettes; Nalutron; Piaponon; Primolut; Progekan; Progestosol; Prolidon; Proluton; Protormone; Syntolutan; Gestron; Lutidon; Lutogyl; Lutren; Prolets; Lutex; Luteal hormone; Lucorteum Sol; Bio-luton; Lutocyclin M; Lipo-Lutin; Luteocrin normale; Luteinique; Prochieve; Prolutone; Lutin; 17alpha-Progesterone; Synovex S; Projestaject; Gynoluton; Gesterol 50; Percutacrine Luteinique; Gesterol 100; Cyclogesterin; Akrolutin; Prolutin; Pregnene-3,20-dione; (S)-Progesterone; Colprosterone; Endometrin; Progesteron; Progestogel; Progeston; 3,20-Pregnene-4; Gelbkoerperhormon; Crinone progesterone gel; Gestiron; Lugesteron; Progestol; Luteol (VAN); Lutocuclin M; .beta.-Progesterone; Percutacrine; (S)-4-Pregnene-3,20-dione; Progeffik; Utrogest; Vitarrine; Luteum; Progesteronum [INN-Latin]; Delta(4)-pregnene-3,20-dione; Progesterona [INN-Spanish]; (S)-Pregn-4-en-3,20-dione; NSC-9704; delta(sup 4)-Pregnene-3,20-dione; CCRIS 533; Prontogest; Estima; 17.alpha.-Progesterone; HSDB 3389; Progesterone [Progestins]; AI3-51682; Prometrium (TN); Pregn-4-en-3,20-dione; UNII-4G7DS2Q64Y; Crinone (TN); 6alpha-Methylpregn-4-en-17alpha-ol-3,20-dione; CHEBI:17026; .delta.4-Pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Pregn-4-ene-3,20-dione, 17alpha-hydroxy-6alpha-methyl-; component of Cyclogesterin; 4-Pregnen-3,20-dione; .delta.(sup4)-Pregnene-3,20-dione; CHEMBL103; D4-Pregnene-3,20-dione; MLS000028517; 4G7DS2Q64Y; NSC9704; NSC64377; MFCD00003658; NSC-64377; Progesterone, 98%; NCGC00015785-04; SMR000058345; DSSTox_CID_2370; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; U 3672; DSSTox_RID_76562; DSSTox_GSID_22370; (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; 6.alpha.-Methylpregn-4-en-17.alpha.-ol-3,20-dione; 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; Progesterona; Progestan; Pregn-4-ene-3,20-dione, 17.alpha.-hydroxy-6.alpha.-methyl-; (1S,10S,11S,14S,15S,2R)-14-acetyl-2,15-dimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0 <11,15>]heptadec-6-ene; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; SMR000653542; Progesterone (Prometrium); WLN: L E5 B666 OV MUTJ A1 E1 FV1; SR-01000000088; SR-01000076054; NSC 9704; EINECS 200-350-6; NSC 64377; Pregn-4-ene-3, 17.alpha.-hydroxy-6.alpha.-methyl-; BHR-100; Duraprogen; Progestrel; Lipolutin; Lutinus; Lutogynon; delta4-Pregnene-3,20-dione; Progesterone??; beta-Progesterone; progesterone group; 1dbb; 17a-Progesterone; CAS-57-83-0; delta(Sup4)-pregnene-3,20-dione; Progesterone [USP:INN:BAN:JAN]; racemic progesterone; Prestwick_411; CIDR; mpp22; 2aa6; 4bb2; Opera_ID_292; PROG;; Progesterone, >=99%; Prestwick0_000477; Prestwick1_000477; Prestwick2_000477; Prestwick3_000477; Spectrum5_002053; Cyclogesterin (Salt/Mix); bmse000482; Epitope ID:116051; EC 200-350-6; Pregn-4-ne-3,20-ione; SCHEMBL7671; BIDD:PXR0094; Lopac0_000895; BSPBio_000614; MLS000758277; MLS001074187; MLS001423982; MLS002222367; BIDD:ER0547; P0130_SIGMA; SPBio_002553; .delta.-Pregnene-3,20-dione; BDBM8903; BPBio1_000676; GTPL2377; Hydroxyprogesterone Caproic acid; DTXSID3022370; Progesterone (JP17/USP/INN); BHR-310; ETI-411; 1a28; 1h60; HMS1569O16; HMS2051O05; HMS2090J07; HMS2096O16; HMS2230F23; HMS2233P11; HMS3262D12; HMS3713O16; Pregnene, 3,20-dione-delta^4-; BCP22000; HY-N0437; ZINC4428529; Tox21_113157; Tox21_201792; Tox21_300307; Tox21_500895; AC-700; CMC_13406; LMST02030159; s1705; SBB012538; AKOS015894908; Progesterone; 4-Pregnene-3,20-dione; ACN-032010; CCG-100766; CS-1937; DB00396; DR-2011; EBD2157912; LP00895; NC00016; SDCCGSBI-0050870.P002; Progesterone 1.0 mg/ml in Acetonitrile; NCGC00022185-03; NCGC00022185-04; NCGC00022185-05; NCGC00022185-06; NCGC00022185-07; NCGC00022185-08; NCGC00022185-09; NCGC00022185-10; NCGC00022185-11; NCGC00022185-12; NCGC00022185-14; NCGC00022185-21; NCGC00090798-01; NCGC00090798-02; NCGC00254120-01; NCGC00259341-01; NCGC00261580-01; AS-12660; CPD000058345; NCI60_042166; ST069329; FE-999913; EU-0100895; P0478; (14beta,17alpha)-pregn-4-ene-3,20-dione; Progesterone, meets USP testing specifications; Progesterone, Vetec(TM) reagent grade, 98%; 6370-EP1441224A2; 6370-EP2269989A1; 6370-EP2269990A1; 6370-EP2275420A1; 6370-EP2284149A1; 6370-EP2289892A1; 6370-EP2292088A1; 6370-EP2292233A2; 6370-EP2292592A1; 6370-EP2295055A2; 6370-EP2295416A2; 6370-EP2298731A1; 6370-EP2298748A2; 6370-EP2298764A1; 6370-EP2298765A1; 6370-EP2298772A1; 6370-EP2305636A1; 6370-EP2305642A2; 6370-EP2308839A1; 6370-EP2308880A1; 6370-EP2311453A1; C00410; D00066; J10165; P 0130; Q26963; S00293; 10324-EP2295503A1; 10324-EP2301536A1; 10324-EP2301538A1; 10324-EP2311455A1; 10324-EP2316452A1; Progesterone, VETRANAL(TM), analytical standard; Q-201624; SR-01000000088-5; SR-01000000088-6; SR-01000076054-1; SR-01000076054-4; BRD-K64994968-001-03-6; 32104FB6-BF81-4F6E-83C2-024DEEAEB272; Progesterone, British Pharmacopoeia (BP) Reference Standard; Progesterone, powder, BioReagent, suitable for cell culture; Progesterone, European Pharmacopoeia (EP) Reference Standard; Progesterone, gamma-irradiated, BioXtra, suitable for cell culture; Progesterone, United States Pharmacopeia (USP) Reference Standard; Progesterone-Water Soluble, powder, BioReagent, suitable for cell culture; Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard; Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard; Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,2R,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 137940-28-4; 753497-20-0; Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
    Click to Show/Hide
Species Origin Dioscorea alata ...     Click to Show/Hide
Dioscorea alata
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Dioscoreales
Family: Dioscoreaceae
Genus: Dioscorea
Species: Dioscorea alata
Disease Preterm labour/delivery [ICD-11: JB00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H30O2
PubChem CID
5994
Canonical SMILES
CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
InChI
1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
InChIKey
RJKFOVLPORLFTN-LEKSSAKUSA-N
CAS Number
CAS 57-83-0
ChEBI ID
CHEBI:17026
Herb ID
HBIN040799
SymMap ID
SMIT00630
TCMSP ID
MOL006214
TTD Drug ID
D07BSQ
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Temozolomide      Brain cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression EGFR  Molecule Info 
Pathway MAP
                    In-vitro Model U-87MG ATCC CVCL_0022 Glioblastoma Homo sapiens
U-118MG CVCL_0633 Glioma Homo sapiens
                    Experimental
                    Result(s)		 PROG enhances the cytotoxic effects of TMZ in GBM cells and reduces its toxic side effects in healthy primary cells.
Target and Pathway
Target(s) Progesterone receptor (PGR)  Molecule Info  [3]
KEGG Pathway Oocyte meiosis Click to Show/Hide
2 Progesterone-mediated oocyte maturation
Pathway Interaction Database Cellular roles of Anthrax toxin Click to Show/Hide
Reactome Nuclear signaling by ERBB4 Click to Show/Hide
2 Nuclear Receptor transcription pathway
WikiPathways Ovarian Infertility Genes Click to Show/Hide
2 Signaling by ERBB4
3 Nuclear Receptors
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2377).
Reference 2 Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide. Biochem Pharmacol. 2018 Nov;157:266-274.
Reference 3 Clinical pipeline report, company report or official report of lipocine.
 Download Picture         KEGG Link